The epigenetic abnormalities are reversible; the application of upregulating 4.1N/EPB41L1 by targeting DNA methylation and miR-454-3p may represent a promising therapy for NSCLC treatment. Here, EPB41L1 is linked to non-small cell lung carcinoma.